BioSpace News Archive

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today will deliver a podium presentation of its research titled “Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs” during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023.

Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023.

Temple Therapeutics presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer.

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.

Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).

AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).

CorMedix Inc. today announced that it will report its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.

Groundbreaking research conducted by a team of leading researchers at Entrinsic Bioscience and the University of Florida revealed significant findings that will change the way we understand amino acid combinations and represents the next generation of Oral Rehydration Solutions.

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it has appointed Bettina M. Cockroft, M.D., M.B.A., to its Board of Directors as an independent director.